98%
921
2 minutes
20
Resistant migraine characterizes those patients who have failed at least three classes of migraine prophylaxis. These difficult-to-treat patients are likely to be characterized by a high prevalence of psychological disturbances. A dysfunction of the endocannabinoid system (ECS), including alteration in the levels of endocannabinoid congeners, may underlie several psychiatric disorders and the pathogenesis of migraines. Here we explored whether the peripheral gene expression of major components of the ECS and the plasma levels of endocannabinoids and related lipids are associated with psychological disorders in resistant migraine. Fifty-one patients (age = 46.0 ± 11.7) with resistant migraine received a comprehensive psychological evaluation according to the DSM-5 criteria. Among the patients, 61% had personality disorders (PD) and 61% had mood disorders (MD). Several associations were found between these psychological disorders and peripheral ECS alterations. Lower plasma levels of palmitoiletanolamide (PEA) were found in the PD group compared with the non-PD group. The MD group was characterized by lower mRNA levels of diacylglycerol lipase α (α) and (cannabinoid-2) receptor. The results suggest the existence of peripheral dysfunction in some components of the ECS and an alteration in plasma levels of PEA in patients with resistant migraine and mood or personality disorders.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10855606 | PMC |
http://dx.doi.org/10.3390/ijms25031893 | DOI Listing |
Pain Med Case Rep
August 2025
Department of Psychiatric Nursing, PIMS, Umarda, Udaipur, Rajasthan, India.
Background: High-frequency transcranial magnetic stimulation (TMS) interventions were approved for migraine headache by the US Food and Drug Administration since 2013; however, it is unclear if 10 Hz frequency repetitive TMS (rTMS) patient relapses, should frequency of TMS be enhanced to 20 Hz protocol? This case series addresses the effectiveness of 20 Hz frequency rTMS in treatment-refractory migraine patients.
Case Report: Five voluntary treatment-refractory migraine patients, referred from Medicine, Neurology, and Neurosurgery departments with mean duration of 11.8 years of migraine, not responding to any medications and failed to respond to 10 Hz frequency standard international guidelines, were subjected to 20 Hz, 5 sessions in the first week followed by weekly sessions for additional 4 weeks.
Pain Manag
September 2025
Department for Neurology, University Clinical Centre of Nis, Nis, Serbia.
Fremanezumab is a monoclonal antibody inhibiting the CGRP signaling leading to migraine prophylaxis. Its efficacy and potential safety concerns are updated here. All available data on fremanezumab were searched in PubMed with emphasis on the mechanisms of action, efficacy, tolerability, and safety.
View Article and Find Full Text PDFCephalalgia
August 2025
Department of Neurology, NeuroClinic Norway, Lillestrom, Norway.
BackgroundThe discovery of calcitonin gene-related peptide (CGRP) as a key player in migraine pathophysiology has revolutionized the approach to preventive treatment. Atogepant, an oral small-molecule CGRP receptor antagonist, has shown promising efficacy in randomized controlled trials (RCTs) for both episodic and chronic migraine. However, real-world evidence, particularly in individuals with chronic migraine and multiple preventive treatment failures, remains limited.
View Article and Find Full Text PDFCephalalgia
August 2025
Bio Behavioral Health, Toms River, NJ, USA.
AimLY3451838 is a monoclonal antibody against pituitary adenylate cyclase-activating peptide (PACAP), a target in migraine research. The present study aimed to evaluate LY3451838 as a preventive treatment for participants with treatment-resistant migraine.MethodsFollowing preclinical assessment of LY3451838, including pharmacokinetic and pharmacodynamic studies, safety was evaluated in a phase 1 study of LY3451838 (n = 33) versus placebo (n = 13) in healthy participants.
View Article and Find Full Text PDFMedicine (Baltimore)
August 2025
Institute of Molecular Biology in Medicine and Gene Therapy, University Center for Health Sciences, University of Guadalajara, Jalisco, Mexico.
Rationale: Hemiplegic migraine (HM) is a rare subtype of migraine characterized by complex aura and transient hemiparesis. It is infrequently associated with refractory focal epilepsy, and there are no previous reports of forced normalization (FN) in this context. This case highlights a novel clinical association and the diagnostic and therapeutic challenges it presents.
View Article and Find Full Text PDF